Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)

Toulouse University Hospital

Status

Completed

Conditions

Parkinson Disease

Treatments

Other: Therapeutic education workshop

Other: Speaking Therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT04228523

RC31/19/0183

2019-A02754-53 (Other Identifier)

Details and patient eligibility

About

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.

Full description

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management.

The therapeutic educational program ETPARK includes individual's consults or workshop. The team frequently offer to patients to participate in workshop on Parkinson disease's drug.

This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.

Enrollment

24 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria,
Patients who are already in therapeutic education program ETPARK,
Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug,
Patients with health insurance,
Patients who have signed a written informed consent form.

Exclusion criteria

Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.),
Patients who has already done workshop on Parkinson disease drug (program ETPARK)
Patients already included in clinical trial during the study,
Patients who have severe psychiatric disorders or dopaminergic psychosis,
Patients with cognitive impairment,
Patients unable to complete the various scales used in the study,
Patients under juridical protection,
Women pregnant or breastfeeding.